R
Rocket Pharmaceuticals, Inc. (RCKT)
NGM – Real vaqt narxi. Valyuta: USD
3.64
+0.05 (1.39%)
Yopilishda: May 12, 2026, 4:00 PM EDT
3.57
-0.07 (-1.92%)
Bozor oldidan: May 13, 2026, 4:10 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
3.64
+0.05 (1.39%)
Yopilishda: May 12, 2026, 4:00 PM EDT
3.57
-0.07 (-1.92%)
Bozor oldidan: May 13, 2026, 4:10 AM EDT
Rocket Pharmaceuticals, Inc. oʻz shoʻba korxonalari bilan birgalikda Qoʻshma Shtatlarda noyob va halokatli kasalliklar uchun gen terapiyasini ishlab chiqish, ishlab chiqarish va sotishga qaratilgan kechki bosqichdagi biotexnologiya kompaniyasi sifatida faoliyat yuritadi. U in vivo adenoviral-associated virus (AAV) dasturlarini ishlab chiqadi, jumladan Danon kasalligi (DD), koʻp organli lizosomal-assotsiatsiyalangan buzilish boʻlib, yurak etishmovchiligi tufayli erta oʻlimga olib keladi (RP-A501), bu 2-bosqichli sinovda; Plakophilin-2 Arrhythmic Cardiomyopathy (PKP2-ACM), bu irsiy yurak kasalligi boʻlib, u yurak mushak massasining progressiv yoʻqolishi, oʻng qorinchaning jiddiy kengayishi, displaziya, miyokardning fibro-yogʻli almashtirilishi va aritmiya va toʻsatdan oʻlimga moyilligi bilan tavsiflanadi (RP-A601), bu 1-bosqichda; va BAG3 Dilated Cardiomyopathy (BAG3-DCM), bu kardiomiopatiyaning bir turi va yurak devorlarining progressiv yupqalashishi bilan tavsiflanadi, bu preklinik bosqichda. Shuningdek, u ex vivo lentiviral (LV) dasturlarini ishlab chiqadi, jumladan Leukotsit Adhesion Deficiency-I (LAD-I), immunitet tizimining notoʻgʻri ishlashiga olib keladigan genetik buzilish (RP-L201); Fanconi Anemia (FA), suyak iligining genetik nuqsoni boʻlib, qon hujayralari ishlab chiqarishni kamaytiradi yoki notoʻgʻri qon hujayralari ishlab chiqarishni ragʻbatlantiradi (RP-L102); va Pyruvate Kinase Deficiency (PKD), qizil qon hujayralarining autosomal retsessiv buzilishi boʻlib, bu surunkali non-sferotsitik gemolitik anemiyaga olib keladi (RP-L301). U Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras va Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; va Temple University bilan litsenzion shartnomalarga ega. Rocket Pharmaceuticals, Inc. 1999-yilda tashkil etilgan va uning shtab-kvartirasi Cranbury, Nyu-Jersi shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Gaurav D. Shah M.D. | CEO & Director |
| Dr. Jonathan Schwartz M.D. | Chief Science & Gene Therapy Officer |
| Dr. Syed Ali-Aamir Rizvi M.D. | Chief Medical Officer |
| Kevin Giordano | Director of Corporate Communications |
| Mr. Christopher Stevens | Chief Operating Officer |
| Mr. John C. Militello CPA | VP of Finance, Senior Controller & Treasurer and Principal Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | rckt-20260331.htm |
| 2026-04-28 | 8-K | ef20071574_8k.htm |
| 2026-04-27 | SC TO-I | ny20069837x2_sctoi.htm |
| 2026-04-06 | DEFA14A | ny20067122x3_defa14a.htm |
| 2026-04-06 | DEF 14A | ny20067122x2_def14a.htm |
| 2026-03-27 | 8-K | ef20069038_8k.htm |
| 2026-03-25 | PRE 14A | ny20067122x1_pre14a.htm |
| 2026-03-10 | 8-K | ef20067503_8k.htm |
| 2026-03-06 | CORRESP | filename1.htm |
| 2026-03-02 | S-3 | ny20066752x1_s3.htm |
| Mr. Martin Louis Wilson J.D. | Gen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer |
| Ms. Meg Dodge J.D., L.L.M. | Senior Vice President & Head of External Affairs |
| Ms. Sarbani Chaudhuri M.B.A. | Chief Commercial & Medical Affairs Officer |